

**CHANGE - ANNOUNCEMENT OF CESSATION::RESIGNATION OF CHIEF OPERATING OFFICER**

## Issuer &amp; Securities

## Issuer/ Manager

HC SURGICAL SPECIALISTS LIMITED

## Securities

HC SURGICAL SPECIALISTSLIMITED - SG1DC2000004 - 1B1

## Stapled Security

No

## Announcement Details

## Announcement Title

Change - Announcement of Cessation

## Date &amp; Time of Broadcast

14-Feb-2022 20:24:14

## Status

New

## Announcement Sub Title

RESIGNATION OF CHIEF OPERATING OFFICER

## Announcement Reference

SG220214OTHR1QRK

## Submitted By (Co./ Ind. Name)

Dr. Heah Sieu Min

## Designation

Executive Director and Chief Executive Officer

## Description (Please provide a detailed description of the event in the box below)

Ms. Ouyang Yuxia, Connie has tendered her resignation as Chief Operating Officer and her last working day with the Company is on 30 April 2022. Her duties will be covered by Ms. Melissa Josephine Tio @ Melissa Josephine Susantio, the existing Operations, Marketing and IT Manager.

HC Surgical Specialists Limited (the "Company") was incorporated on 1 September 2015 in Singapore and listed on Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures across a network of 16 clinics located throughout Singapore.

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no

responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

---

### Additional Details

---

#### Name Of Person

Ouyang Yuxia, Connie

---

#### Age

38

---

#### Is effective date of cessation known?

Yes

---

#### If yes, please provide the date

01/05/2022

---

#### Detailed Reason (s) for cessation

Ms. Ouyang Yuxia, Connie has resigned to pursue other career opportunities.

After having interviewed Ms. Ouyang Yuxia, Connie and to the best of its knowledge, the Company's sponsor, Novus Corporate Finance Pte. Ltd. is satisfied that save as disclosed in this announcement, there are no other material reasons for the resignation of Ms. Ouyang Yuxia, Connie as Chief Operating Officer of the Company.

---

#### Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?

No

---

#### Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?

No

---

#### Any other relevant information to be provided to shareholders of the listed issuer?

No

---

#### Date of Appointment to current position

01/06/2017

---

#### Does the AC have a minimum of 3 members (taking into account this cessation)?

Yes

---

#### Number of Independent Directors currently resident in Singapore (taking into account this cessation)

2

---

#### Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months

1

---

#### Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)

Chief Operating Officer

---

**Role and responsibilities**

As Chief Operating Officer, Ms. Ouyang Yuxia, Connie is responsible for the overall operation of the Group's clinics, including ensuring that every clinic conforms to a common operating procedure and process, and adheres to stringent standard of procedures, clinical guidelines and safety procedures.

---

**Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries**

No

---

**Shareholding interest in the listed issuer and its subsidiaries?**

Yes

---

**Shareholding Details**

51,100 ordinary shares

---

**Past (for the last 5 years)**

None

---

**Present**

None

---